Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01826448 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01826448 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 13 participants.
The verdict
NCT01826448, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of unresectable or metastatic melanoma.
Interventions
- DRUG vemurafenib
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-11-05 |
| Est. Completion | 2014-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01826448
The ClinicalTrials.gov registry entry for NCT01826448 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vemurafenib is the first listed.
NCT01826448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01826448 about?
NCT01826448 is a clinical study titled "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma". The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA)...
What is the current status of trial NCT01826448?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-11-05. Estimated completion is 2014-09-22.
What interventions are being tested in trial NCT01826448?
The interventions under investigation include: vemurafenib (DRUG), PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01826448?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.